DNA Electronics Ltd (DNAe), a developer of semiconductor solutions for real-time DNA and RNA detection, today announces that it had successfully secured the necessary funding for DNAe to develop the Genalysis® point-of-care genomic diagnostic product line. The majority of the funding had been provided by its principal shareholder, Edith Grove Limited (a wholly owned subsidiary of Genting Berhad), with the company’s founders also making further investment. DNAe will utilise the funding to transform the company from an R&D and licensing business to a full-fledged product company, offering point-of-care solutions for time-critical medical applications.
Amgen (AMGN), Massachusetts General Hospital (MGH) and the Broad Institute have entered inot a strategic collaboration to jointly discover and validate new therapeutic targets and develop novel therapies for inflammatory bowel disease (IBD).
Thermo Fisher Scientific has introduced two new solvent delivery systems-Accela 600 HPLC and Accela 1000 U-HPLC. These enable rapid method development, reduce solvent consumption and consequently, enhance laboratory efficiency.
These Accela systems' Force Feedback Control (FFC) features render accurate and precise gradients under all operating conditions and flexibility to quaternary solvent delivery.
Used with Thermo Scientific Hypersil columns packed with 5, 3 and the new 2.4 micron particle diameter, the Accela 600 provides flow rates up to 5 mL / min and a maximum operating pressure of 600 bar with 90 µL of delay volume. The Accela 1000 has a maximum operating pressure of 1000 bar with 65 µL of delay volume.
The Accela PDA improves sample identification with increased sensitivity and has an acquisition rate up to 80 Hz. The PDA's LightPipe technology enables fast separations by employing a 1 cm path length in a 2 µL flow cell. The low level of dispersion in the LightPipe technology allows the flowcell to retain peak shape and chromatographic resolution. The Accela U-HPLC system optimises the performance of sub-2 µm particle columns.
AvidBiotics has received new Small Business Innovation Research (SBIR) grant from the National Institute of Allergic and Infectious Diseases of the National Institutes of Health to further develop targetable bactericidal proteins to kill Clostridium difficile bacteria.
Laboratory Corporation of America® Holdings today announced that it is offering the COBAS AmpliPrep/COBAS TaqMan HCV Test v2.0. With enhanced sensitivity this quantitative viral load assay for Hepatitis C virus (HCV) enables more accurate assessments of response to antiviral therapy.
Researchers at the Massachusetts Institute of Technology (MIT) have created the first fully synthetic nanoparticles that can penetrate a cell membrane without rupturing the protective membrane and thereby killing it.
Venous thromboembolism (VTE) is the term used to describe a condition in which a blood clot (a thrombus) forms in a vein and then dislodges to travel in the blood (an embolus). A venous thrombus most commonly occurs in the deep veins of the legs or pelvis; this is called deep vein thrombosis (DVT).